RE:Valuation of a anti-virus platform Even before COVID-19 existed, here's the
425M$US deal (and 120M$US upfront payment) BioNtech got from Pfizer for a mNRA platform
that had back then proven nothing in humans. Moderna obtained 500M$US in similar financing.
So TLT's anti-virus platform will be given a value if we proceed with a jv partner.
August 2018:
Pfizer pays BioNTech $120M upfront to form mRNA flu vaccine pact Pfizer has struck a $425 million deal to work with BioNTech on the development of mRNA influenza vaccines. The Big Pharma is providing $120 million in upfront and near-term payments to enter into the R&D collaboration.
Germany’s BioNTech has established itself at the forefront of the mRNA field, leading to deals with Eli Lilly, Genentech and Sanofi and a $270 million series A. Many of the collaborations, plus BioNTech’s internal programs, are using mRNA to activate the immune system against tumors. But the approach could also yield prophylactic vaccines that are more potent and easier to make than existing shots.
The vaccines will deliver RNA encoding for an antigen. Once the antigen is produced, it induces T cell responses that prime the immune system to spot the protein. The approach could cut the time it takes to develop and manufacture vaccines in response to emerging pandemic threats, and induce protection against multiple proteins.
BioNTech has talked up the idea for several years but has been occupied by its oncology programs. Now, Pfizer is stepping up to get the project motoring forward.
“mRNA vaccines offer a novel approach to code for any protein or multiple proteins, and the potential to manufacture higher potency flu vaccines more rapidly and at a lower cost than contemporary flu vaccines,” Kathrin Jansen, head of Pfizer’s vaccine R&D unit, said in a statement.
Dec. 2019, that was after BioNtech 425M$US jv with Pfizer on influenza vaccine in 2018. In Dec. 2019, BioNtech was then already trading @34$US.
Then, in July 2021:
If You Invested $10,000 in BioNTech in 2019, This Is How Much You Would Have Today Trading at only $34US
If you had invested $10,000 in BioNTech back in December 2019, you would have gotten about 294 shares. The stock was trading at about $34 a share on Dec. 31. Today, BioNTech is trading at about $217 a share. That means your investment would be worth $63,798 right now.
The shares have moved progressively higher since our imaginary $10,000 investment. But the movement intensified this spring. Why? BioNTech reported a billion-dollar quarterly profit thanks to COVID-19 vaccine sales.
Imagine one that would have invested in July 2018 in BioNtech.
So our investment in TLT is a 10x bagger easily if NMIBC data keeps delivering.